Dactinomycin

Indication: Rhabdomyosarcoma primary site
ICD11 code: 2C25.Z

INN: Dactinomycin

Medicine type: Chemical agent

List type: Complementary

Formulations: Parenteral > General injections > IV: 500 µg in vial powder for injection

EML status history:
First added in 1984 (TRS 722)
Changed in 2015 (TRS 994)

Sex: All

Age: Also recommended for children

Therapeutic alternatives: The recommendation is for this specific medicine

Patent information: Patents have expired in most jurisdictions
Read more about patents.

Tags: Cancer

Wikipedia: Dactinomycin

DrugBank: Dactinomycin

Summary of evidence and Expert Committee recommendations

In 2015, as part of the comprehensive review of cancer medicines undertaken by the Expert Committee, listing for dactinomycin on the complementary list of the EML and EMLc for use in treatment protocols for rhabdomyosarcoma was specifically endorsed. The relevant extracts from TRS994 regarding the Expert Committee's 2015 consideration of treatment protocols for rhabdomyosarcoma is attached.

Expert Committee report